Health Condition 1: L210- Seborrhea capitis
Conditions
Interventions
Intervention1: K3N Shampoo: Water (Aqua), Sodium Laureth Sulfate, Dimethiconol (and) TEA-Dodecylbenzenesulfonate,
Cocamidopropyl Betaine, Ethylene Glycol Distearate, PEG-7 Glyceryl Cocoate, Cocamide
Sponsors
CavinKare Private Limited., India
Eligibility
Inclusion criteria
Inclusion criteria: Male and female participants aged between 18 and 45 years. 2. A total Participants with moderate-to-severe dandruff will be enrolled in a ratio of 40 (moderate) :60 (severe)/ 30 (moderate) :70 (severe). 3. Participants who are committed not to use medicated/non medicated shampoos/soaps (including soaps containing antibacterial/antifungal agents) or any other antidandruff treatment/hair products (including prescription and non- prescription medications such as hair oil, conditioners) for the entire duration of the study. 4. Participants will be asked to use the shampoo 2 times a week and accepting to follow this procedure during the whole study period. 5. Participants who did not participated in any other clinical trial during the past 3 months.
Exclusion criteria
Exclusion criteria: Scalp Psoriasis. 2. Participants who underwent any type of hair procedures within the past 2 weeks or during the study. 3. Participants with immediate life-threatening diseases such as pre- existing cardiovascular, liver or neoplastic disease. 4. Participants undergoing treatment for immune-compromised conditions/psychiatric illness. 5. Participants with any other co- morbid conditions like diabetes that can affect the study outcome. 6. Pregnant or lactating women 7. Hypersensitivity to any of the components of the test formulation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Total Dandruff Severity Score (TDSS) 2. Hair performance (Investigator & participant Assessment) 3. Global Improvement Assessment 4. Scalp Condition Scoring (Dermatologist Assessment) 5. To assess DLQI (Dermatology Life Quality Index) 6. Assessment of recurrence at the end of the study. Timepoint: Visit 1 (Day 0 - D), Visit 2 (D+7), Visit 3 (D+8), Visit 4 (D+9), Visit 5 (D+14), Visit 6 (D+21) and Visit 7 (D+35) | — |
Secondary
| Measure | Time frame |
|---|---|
| To monitor for any adverse events during the study period. Timepoint: Baseline upto 6 weeks | — |
Countries
India
Contacts
Public ContactDr Gayathri Sivakumar
DK Elite Health Care Centre
Outcome results
None listed